FDA agrees to review application for Simponi biosimilar
The U.S. Food and Drug Administration (FDA) has agreed to review an application seeking approval of AVT05, a proposed biosimilar for Simponi (golimumab), which is an approved treatment for ankylosing spondylitis. Developers Alvotech and Teva Pharmaceuticals said this marks the first time that the FDA has…